ClinicalTrials.gg
Active, not recruitingNCT02763566MONARCH plusUpdated Feb 5, 2026Results posted

A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer

A Phase 3 interventional study of Abemaciclib and Anastrozole in Breast Cancer, sponsored by Eli Lilly and Company. Active, not recruiting at 45 sites in 4 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-05.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
463
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 55 studies testing abemaciclib in Breast Neoplasms — 22 open to participants now, 34 under way, 10 of them phase 3. abemaciclib · Breast Neoplasms.

Enrollment
7th of 55
463 · median 120
Started
2016
with 4 others
Phase 3
11 of 55
2 open now
Primary completion
2019-03
later than 2 of 33 live
Registered
9th of 55
by date
Lead sponsor
17 of 55
Eli Lilly and Company

Among the 55 studies testing abemaciclib in Breast Neoplasms, this one is the 7th largest by enrollment, is one of 5 that started in 2016, is one of 11 in phase 3, reaches primary completion later than 2 of the 33 other live ones, and was the 9th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

22 of the 55 studies testing abemaciclib in Breast Neoplasms are open now, in 6 countries. Recruiting first, the newest first:

17 more — sign in →

By country, each count listing its studies:

All 22 open studies →

About abemaciclib

abemaciclib: first FDA approval 2017 (VERZENIO), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies testing abemaciclib in Breast Neoplasms, or all of them as a file.
02

Study summary

The main purpose of this study is to evaluate the efficacy of the study drug abemaciclib in postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) locoregionally recurrent or metastatic breast cancer.

03

Conditions studied

  • Breast Cancer

Browse trials for

Keywords

  • Hormone Receptor-Positive
  • HER2-Negative
  • CDK4
  • CDK6
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a diagnosis of HR+, - breast cancer. Although not required as a protocol procedure, disease should be considered for whenever possible to reassess hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2) status if clinically indicated.

    • To fulfill the requirement for HR+ disease, a breast cancer must express, by immunohistochemistry (IHC), at least 1 of the HRs (estrogen receptor [ER], progesterone receptor [PgR]) as defined in the relevant American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines.
    • To fulfill the requirement of HER2- disease, a breast cancer must not demonstrate, at initial diagnosis or upon subsequent biopsy, overexpression of HER2 by either IHC or in-situ hybridization as defined in the relevant ASCO/CAP guidelines.
  • Meet either Inclusion Criterion (2a) or Inclusion Criterion (2b). Participants meeting Inclusion Criterion 2a will be enrolled in Cohort A and participants meeting Inclusion Criterion 2b will be enrolled in Cohort B.
  • (2a) Have locoregionally recurrent disease not amenable to resection or radiation therapy with curative intent or metastatic disease.

    • with radiologic evidence of progression more than 1 year from completion of endocrine therapy and have received no prior endocrine therapy for locoregionally recurrent or metastatic disease (Note: prior adjuvant endocrine therapy for localized disease may have included, but is not limited to, anti-estrogens or aromatase inhibitors. In addition, a participant may be enrolled if she has received ≤2 weeks of NSAI in this disease setting immediately preceding screening and agrees to discontinue NSAI until study treatment initiation.) OR
    • Presented with de novo metastatic breast cancer (mBC) and not received any prior endocrine therapy. OR
  • Relapsed with radiologic evidence of progression less than 1 year from completion of or while receiving adjuvant endocrine therapy (except for letrozole or anastrozole) and have received no prior endocrine therapy for locoregionally recurrent or metastatic disease.
  • (2b) Have locoregionally recurrent disease not amenable to resection or radiation therapy with curative intent or metastatic disease.

    • Relapsed with radiologic evidence of progression while receiving neoadjuvant or adjuvant endocrine therapy, with no subsequent endocrine therapy received following progression OR
    • Relapsed with radiologic evidence of progression within 1 year from completion of adjuvant endocrine therapy, with no subsequent endocrine therapy received following progression OR
    • Relapsed with radiologic evidence of progression more than 1 year from completion of adjuvant endocrine therapy and then subsequently relapsed with radiologic evidence of progression after receiving treatment with either an antiestrogen or an aromatase inhibitor as firstline endocrine therapy for metastatic disease. Participants may not have received more than 1 line of endocrine therapy or any prior chemotherapy for metastatic disease OR
    • Presented with de novo metastatic disease and then relapsed with radiologic evidence of progression after receiving treatment with either an antiestrogen or an aromatase inhibitor as endocrine therapy for metastatic disease. Participants may not have received more than 1 line of endocrine therapy or any prior chemotherapy for metastatic disease.
  • Have status defined as meeting at least 1 of the following:

    • Prior bilateral oophorectomy
    • Age ≥60 years
    • Age \<60 years and amenorrheic for at least 12 months (in the absence of chemotherapy, tamoxifen, toremifene, or ovarian suppression) and follicle-stimulating hormone (FSH) and estradiol levels in the postmenopausal range.
  • Have 1 of the following, as defined by the (RECIST) v1.1:

    • Nonmeasurable bone-only disease. Nonmeasurable bone-only disease may include any of the following: blastic bone lesions, lytic bone lesions without a measurable soft tissue component, or mixed lytic-blastic bone lesions without a measurable soft tissue component.
  • Have a performance status (PS) of ≤1 on the Eastern Cooperative Oncology () scale.
  • Have adequate organ function, including:

    • Hematologic: (ANC) ≥1.5 × 109/Liter (L),

      ≥100 × 109/L, and ≥8 g/deciliter (dL). Participants may receive erythrocyte transfusions to achieve this hemoglobin level at the discretion of the investigator; however, initial study drug treatment must not begin earlier than the day after the erythrocyte transfusion.

    • Hepatic: Total ≤1.5 times the (ULN) and (ALT) and aspartate aminotransferase (AST)

      ≤3.0 times ULN (or ALT and AST ≤5 times ULN if liver metastases are present).

    • Renal: serum creatinine ≤1.5 times ULN.
  • Have discontinued previous localized radiotherapy for palliative purposes or for lytic lesions at risk of fracture at least 2 weeks prior to randomization and recovered from the acute effects of therapy (until the toxicity resolves to either baseline or at least Grade 1) except for residual alopecia or peripheral neuropathy.
  • Are able to swallow capsules.
  • Are reliable, willing to be available for the duration of the study, and willing to follow study procedures.

Exclusion criteria

Exclusion Criteria:

  • Have visceral crisis, lymphangitic spread, or . Visceral crisis is not the mere presence of visceral , but implies severe organ dysfunction as assessed by symptoms and signs, laboratory studies, and rapid progression of the disease.
  • Have inflammatory breast cancer.
  • Have clinical evidence or a history of central nervous system (CNS) metastasis. Screening test is not required for enrollment.
  • Are currently receiving or have previously received chemotherapy for locoregionally recurrent or metastatic breast cancer. (Note: Participants may be enrolled if they received prior [neo] chemotherapy for localized disease.)
  • Have received prior treatment with everolimus or fulvestrant (for Cohort B only).
  • Have received prior treatment with any cyclin-dependent kinases 4 and 6 (CDK4 and CDK6) inhibitor (or participated in any CDK4 and CDK6 inhibitor clinical trial for which treatment assignment is still blinded).
  • Have initiated bisphosphonates or approved Receptor activator of nuclear factor kappa-B ligand (RANK-L) targeted agents \<7 days prior to randomization.
  • Are currently enrolled in a clinical trial involving an product (IP) or non-approved use of a drug or device (other than the IP/device used in this study), or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study. If a participant is currently enrolled in a clinical trial involving non-approved use of a device, then agreement with the investigator and Eli Lilly and Company (Lilly) clinical research physician (CRP) is required to establish eligibility.
  • Have received treatment with a drug that has not received regulatory approval for any indication within 14 or 21 days of randomization for a nonmyelosuppressive or myelosuppressive agent, respectively.
  • Have had major surgery within 14 days prior to randomization to allow for post-operative healing of the surgical wound and site(s).
  • Have received recent (within 28 days prior to randomization) such as yellow fever vaccine.
  • Have serious preexisting medical conditions that, in the judgment of the investigator, would preclude participation in this study (eg, history of major surgical resection involving the stomach or small bowel, or preexisting Crohn's disease or ulcerative colitis).
  • Have a personal history within the last 12 months of any of the following conditions: syncope of cardiovascular etiology, ventricular tachycardia, ventricular fibrillation, or sudden cardiac arrest.
  • Have a history of any other cancer (except nonmelanoma skin cancer or carcinoma in-situ of the cervix), unless in complete remission with no therapy for a minimum of 3 years.
  • Have received an or allogeneic stem-cell transplant.
  • Have clinical evidence of active bacterial or fungal infection or active viral infection that, in the judgment of the investigator, would preclude participation in this study (eg, [HIV] or viral hepatitis). Screening test is not required for enrollment.
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
463 participants (actual)

Study arms

  • Experimental
    Abemaciclib + Nonsteroidal Aromatase Inhibitor (NSAI)

    Abemaciclib given orally every 12 hours (Q12H) plus anastrozole or letrozole given orally every 24 hours (Q24H) on days 1 to 28 of a 28 day cycle. Participants receiving benefit may continue until disease progression.

    Drug: Abemaciclib · Drug: Anastrozole · Drug: Letrozole

  • Experimental
    Placebo + NSAI

    Placebo given orally Q12H plus anastrozole or letrozole given orally Q24H on days 1 to 28 of a 28 day cycle. Participants receiving benefit may continue until disease progression.

    Drug: Anastrozole · Drug: Letrozole · Drug: Placebo

  • Experimental
    Abemaciclib + Fulvestrant

    Abemaciclib given orally Q12H on days 1 to 28 of a 28 day cycle plus fulvestrant intramuscularly (IM) on days 1 and 15 of cycle 1, then on day 1 of cycle 2 and beyond. Participants receiving benefit may continue until disease progression.

    Drug: Abemaciclib · Drug: Fulvestrant

  • Experimental
    Placebo + Fulvestrant

    Placebo given orally Q12H on days 1 to 28 of a 28 day cycle plus fulvestrant IM on days 1 and 15 of cycle 1, then on day 1 of cycle 2 and beyond. Participants receiving benefit may continue until disease progression.

    Drug: Placebo · Drug: Fulvestrant

Interventions

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS) (Abemaciclib + NSAI & Placebo NSAI)

    Progression-free survival time was measured from randomization until the date of objective progression as defined by Response Evaluation Criteria in Solid Tumors v1.1 (RECIST v1.1), or death from any cause. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. Patients who have neither progressed nor died were censored at the day of their last radiographic tumor assessment, if available, or date of randomization if no post-baseline radiographic assessment is available.

    Time frame: Randomization to Measured Progressive Disease or Death (up to 26 Months)

Secondary outcomes

  1. Progression Free Survival (PFS) (Abemaciclib + Fulvestrant and Placebo + Fulvestrant Arms)

    Progression-free survival time was measured from randomization until the date of objective progression as defined by Response Evaluation Criteria in Solid Tumors v1.1 (RECIST v1.1), or death from any cause. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. Patients who have neither progressed nor died were censored at the day of their last radiographic tumor assessment, if available, or date of randomization if no post-baseline radiographic assessment is available.

    Time frame: Randomization to Measured Progressive Disease or Death (up to 26 Months)

  2. Overall Survival (OS)

    Time frame: Randomization to Date of Death from Any Cause (Estimated up to 38 Months)

  3. Percentage of Participants With Best Overall Response (BOR) of Complete Response (CR) or Partial Response (PR) [Objective Response Rate (ORR)]

    Objective response rate is the percentage of participants with a BOR of CR or PR as defined by RECIST v1.1. CR is defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR is defined as at least a 30% decrease in the sum of the LD of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions.

    Time frame: Randomization to Measured Progressive Disease (up to 26 Months)

  4. Duration of Response (DoR)

    Time frame: Date of CR or PR to Date of Objective Disease Progression or Death Due to Any Cause (Estimated up to 38 Months)

  5. Percentage of Participants Who Exhibit Stable Disease (SD) or CR or PR [Disease Control Rate (DCR)]

    Disease control rate (DCR) is the percentage of participants with a best overall response of CR, PR or SD as defined by RECIST v1.1. CR is defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR is defined as at least a 30% decrease in the sum of the longest diameter (LD) of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. SD is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD) for target lesions, no progression of non-target lesions, and no appearance of new lesions. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions.

    Time frame: Randomization to Measured Progressive Disease (up to 26 Months)

  6. Percentage of Participants With Best Overall Response of CR, PR, or SD With Duration of SD for at Least 6 Months [Clinical Benefit Rate (CBR)]

    Clinical benefit rate (CBR) is the percentage of participants with a BOR of CR or PR, or SD for at least 6 months. CR is defined as the disappearance of all target and non-target lesions \& no appearance of new lesions. PR is defined as at least a 30% decrease in the sum of the LD of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. SD is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD for target lesions, no progression of non-target lesions, and no appearance of new lesions. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions.

    Time frame: Randomization to Measured Progressive Disease (up to 26 Months)

  7. Change From Randomization in Symptom Burden on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30)

    consists of 30 items covered by 1 of 3 dimensions: 1. Global health status/quality of life (2 items) with scores ranging from 1 (Very Poor) to 7 (Excellent). 2. Functional scales (15 total items addressing either physical, role, emotional, cognitive, or social functioning), each item scores ranging from 1 (not at all) to 4 (very much) 3. Symptom scales (13 total items addressing either fatigue, nausea/vomiting, pain, dyspnea, insomnia, appetite loss, constipation, diarrhea, or financial impact), each item scores ranging from 1 (not at all) to 4 (very much). Raw scores are linearly converted to a 0-100 scale with higher scores reflecting higher levels of function/QOL or higher levels of symptom burden.

    Time frame: Baseline through 19 Months

  8. Pharmacokinetics (PK): Area Under the Concentration Curve of Abemaciclib, Its Metabolites (M2 & M20)

    Pharmacokinetics (PK): Area Under the Concentration Curve of Abemaciclib and its Metabolites LSN2839567 (M2) \& LSN3106726 (M20) was reported. C=Cycle, D=day;

    Time frame: C1D1 post dose, C2D1 post dose, C3D1 predose, C4D1 predose

07

Results

Posted Mar 30, 2020

Participant flow

Participant flow — Overall Study
MilestoneAbemaciclib + Nonsteroidal Aromatase Inhibitor (NSAI)Placebo + NSAIAbemaciclib + FulvestrantPlacebo + Fulvestrant
Started2079910453
Completed89605039
Not completed118395414
Withdrew: Lost to follow-up1401
Withdrew: On study treatment at study conclusion114345413
Withdrew: Withdrawal by subject3100

Outcome measures

PrimaryProgression Free Survival (PFS) (Abemaciclib + NSAI & Placebo NSAI)

Progression-free survival time was measured from randomization until the date of objective progression as defined by Response Evaluation Criteria in Solid Tumors v1.1 (RECIST v1.1), or death from any cause. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. Patients who have neither progressed nor died were censored at the day of their last radiographic tumor assessment, if available, or date of randomization if no post-baseline radiographic assessment is available.

Time frame:
Randomization to Measured Progressive Disease or Death (up to 26 Months)
Reported as:
Median · Months
Progression Free Survival (PFS) (Abemaciclib + NSAI & Placebo NSAI)
MonthsAbemaciclib + Nonsteroidal Aromatase Inhibitor (NSAI)Placebo + NSAI
Progression Free Survival (PFS) (Abemaciclib + NSAI & Placebo NSAI)NA (22.32 to NA)14.73 (11.21 to 18.87)
Statistical analysis
  • Abemaciclib + Nonsteroidal Aromatase Inhibitor (NSAI) vs Placebo + NSAI · Log Rank · p = 0.0001 · Hazard ratio (hr): 0.499 · 95% CI 0.346 to 0.719
SecondaryProgression Free Survival (PFS) (Abemaciclib + Fulvestrant and Placebo + Fulvestrant Arms)

Progression-free survival time was measured from randomization until the date of objective progression as defined by Response Evaluation Criteria in Solid Tumors v1.1 (RECIST v1.1), or death from any cause. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. Patients who have neither progressed nor died were censored at the day of their last radiographic tumor assessment, if available, or date of randomization if no post-baseline radiographic assessment is available.

Time frame:
Randomization to Measured Progressive Disease or Death (up to 26 Months)
Reported as:
Median · Months
Progression Free Survival (PFS) (Abemaciclib + Fulvestrant and Placebo + Fulvestrant Arms)
MonthsAbemaciclib + FulvestrantPlacebo + Fulvestrant
Progression Free Survival (PFS) (Abemaciclib + Fulvestrant and Placebo + Fulvestrant Arms)11.47 (9.53 to NA)5.59 (3.65 to 7.69)
Statistical analysis
  • Abemaciclib + Fulvestrant vs Placebo + Fulvestrant · Log Rank · p = <0.0001 · Hazard ratio (hr): 0.376 · 95% CI 0.240 to 0.588
SecondaryOverall Survival (OS)
Time frame:
Randomization to Date of Death from Any Cause (Estimated up to 38 Months)

Results for this outcome have not been posted.

SecondaryPercentage of Participants With Best Overall Response (BOR) of Complete Response (CR) or Partial Response (PR) [Objective Response Rate (ORR)]

Objective response rate is the percentage of participants with a BOR of CR or PR as defined by RECIST v1.1. CR is defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR is defined as at least a 30% decrease in the sum of the LD of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions.

Time frame:
Randomization to Measured Progressive Disease (up to 26 Months)
Reported as:
Number · percentage of participants
Percentage of Participants With Best Overall Response (BOR) of Complete Response (CR) or Partial Response (PR) [Objective Response Rate (ORR)]
percentage of participantsAbemaciclib + Nonsteroidal Aromatase Inhibitor (NSAI)Placebo + NSAIAbemaciclib + FulvestrantPlacebo + Fulvestrant
Percentage of Participants With Best Overall Response (BOR) of Complete Response (CR) or Partial Response (PR) [Objective Response Rate (ORR)]56.0 (49.3 to 62.8)30.3 (21.3 to 39.4)38.5 (29.1 to 47.8)7.5 (0.4 to 14.7)
Statistical analysis
  • Abemaciclib + Nonsteroidal Aromatase Inhibitor (NSAI) vs Placebo + NSAI · Cochran-Mantel-Haenszel · p = <0.0001
  • Abemaciclib + Fulvestrant vs Placebo + Fulvestrant · Cochran-Mantel-Haenszel · p = <0.0001
SecondaryDuration of Response (DoR)
Time frame:
Date of CR or PR to Date of Objective Disease Progression or Death Due to Any Cause (Estimated up to 38 Months)

Results for this outcome have not been posted.

SecondaryPercentage of Participants Who Exhibit Stable Disease (SD) or CR or PR [Disease Control Rate (DCR)]

Disease control rate (DCR) is the percentage of participants with a best overall response of CR, PR or SD as defined by RECIST v1.1. CR is defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR is defined as at least a 30% decrease in the sum of the longest diameter (LD) of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. SD is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD) for target lesions, no progression of non-target lesions, and no appearance of new lesions. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions.

Time frame:
Randomization to Measured Progressive Disease (up to 26 Months)
Reported as:
Number · percentage of participants
Percentage of Participants Who Exhibit Stable Disease (SD) or CR or PR [Disease Control Rate (DCR)]
percentage of participantsAbemaciclib + Nonsteroidal Aromatase Inhibitor (NSAI)Placebo + NSAIAbemaciclib + FulvestrantPlacebo + Fulvestrant
Percentage of Participants Who Exhibit Stable Disease (SD) or CR or PR [Disease Control Rate (DCR)]91.3 (87.5 to 95.1)82.8 (75.4 to 90.3)92.3 (87.2 to 97.4)69.8 (57.5 to 82.2)
Statistical analysis
  • Abemaciclib + Nonsteroidal Aromatase Inhibitor (NSAI) vs Placebo + NSAI · Cochran-Mantel-Haenszel · p = 0.0456
  • Abemaciclib + Fulvestrant vs Placebo + Fulvestrant · Cochran-Mantel-Haenszel · p = 0.0004
SecondaryPercentage of Participants With Best Overall Response of CR, PR, or SD With Duration of SD for at Least 6 Months [Clinical Benefit Rate (CBR)]

Clinical benefit rate (CBR) is the percentage of participants with a BOR of CR or PR, or SD for at least 6 months. CR is defined as the disappearance of all target and non-target lesions \& no appearance of new lesions. PR is defined as at least a 30% decrease in the sum of the LD of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. SD is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD for target lesions, no progression of non-target lesions, and no appearance of new lesions. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions.

Time frame:
Randomization to Measured Progressive Disease (up to 26 Months)
Reported as:
Number · percentage of participants
Percentage of Participants With Best Overall Response of CR, PR, or SD With Duration of SD for at Least 6 Months [Clinical Benefit Rate (CBR)]
percentage of participantsAbemaciclib + Nonsteroidal Aromatase Inhibitor (NSAI)Placebo + NSAIAbemaciclib + FulvestrantPlacebo + Fulvestrant
Percentage of Participants With Best Overall Response of CR, PR, or SD With Duration of SD for at Least 6 Months [Clinical Benefit Rate (CBR)]82.6 (77.4 to 87.8)62.6 (53.1 to 72.2)77.9 (69.9 to 85.9)45.3 (31.9 to 58.7)
Statistical analysis
  • Abemaciclib + Nonsteroidal Aromatase Inhibitor (NSAI) vs Placebo + NSAI · Cochran-Mantel-Haenszel · p = 0.0003
  • Abemaciclib + Fulvestrant vs Placebo + Fulvestrant · Cochran-Mantel-Haenszel · p = <0.0001
SecondaryChange From Randomization in Symptom Burden on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30)

consists of 30 items covered by 1 of 3 dimensions: 1. Global health status/quality of life (2 items) with scores ranging from 1 (Very Poor) to 7 (Excellent). 2. Functional scales (15 total items addressing either physical, role, emotional, cognitive, or social functioning), each item scores ranging from 1 (not at all) to 4 (very much) 3. Symptom scales (13 total items addressing either fatigue, nausea/vomiting, pain, dyspnea, insomnia, appetite loss, constipation, diarrhea, or financial impact), each item scores ranging from 1 (not at all) to 4 (very much). Raw scores are linearly converted to a 0-100 scale with higher scores reflecting higher levels of function/QOL or higher levels of symptom burden.

Time frame:
Baseline through 19 Months
Reported as:
Least squares mean · score on a scale
Change From Randomization in Symptom Burden on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30)
score on a scaleAbemaciclib + Nonsteroidal Aromatase Inhibitor (NSAI)Placebo + NSAIAbemaciclib + FulvestrantPlacebo + Fulvestrant
Global Health Status2.38 ± 0.994.26 ± 1.47-0.35 ± 1.413.12 ± 2.07
Functional Scales - Physical Functioning-0.78 ± 0.82-0.01 ± 1.21-1.11 ± 1.06-2.70 ± 1.54
Functional Scales - Role Functioning-1.69 ± 1.20-1.38 ± 1.79-3.76 ± 1.35-2.04 ± 1.95
Functional Scales - Emotional Functioning1.57 ± 0.98-0.10 ± 1.440.43 ± 1.270.18 ± 1.85
Functional Scales - Cognitive Functioning-2.89 ± 0.90-0.72 ± 1.35-3.52 ± 1.35-1.10 ± 1.96
Functional Scales - Social Functioning-2.45 ± 1.19-1.57 ± 1.75-2.03 ± 1.71-2.67 ± 2.44
Symptom Scales - Fatigue1.63 ± 0.950.06 ± 1.404.19 ± 1.441.46 ± 2.08
Symptom Scales - Nausea and Vomiting0.62 ± 0.60-0.33 ± 0.884.26 ± 1.101.67 ± 1.65
Symptom Scales - Pain-5.44 ± 0.91-4.90 ± 1.35-2.82 ± 1.36-0.17 ± 2.01
Symptom Scales - Dyspnoea2.51 ± 1.020.35 ± 1.53-1.66 ± 1.270.83 ± 1.92
Symptom Scales - Insomnia-0.87 ± 1.07-0.05 ± 1.601.53 ± 1.59-0.44 ± 2.42
Symptom Scales - Appetite4.19 ± 0.97-1.47 ± 1.448.67 ± 1.631.21 ± 2.42
Symptom Scales - Constipation-3.05 ± 0.98-1.49 ± 1.46-1.63 ± 1.310.65 ± 1.88
Symptom Scales - Diarrhoea15.72 ± 0.85-0.10 ± 1.2716.03 ± 1.26-1.80 ± 1.95
Symptom Scales - Financial Difficulties-3.02 ± 1.65-1.27 ± 2.46-6.36 ± 1.76-9.35 ± 2.59
Statistical analysis
  • Abemaciclib + Nonsteroidal Aromatase Inhibitor (NSAI) vs Placebo + NSAI · Mixed Models Analysis · p = 0.287 · Lsmean difference: -1.89 · 95% CI -5.36 to 1.59
  • Abemaciclib + Nonsteroidal Aromatase Inhibitor (NSAI) vs Placebo + NSAI · Mixed Models Analysis · p = 0.597 · Lsmean difference: -0.77 · 95% CI -3.64 to 2.10
  • Abemaciclib + Nonsteroidal Aromatase Inhibitor (NSAI) vs Placebo + NSAI · Mixed Models Analysis · p = 0.885 · Lsmean difference: -0.31 · 95% CI -4.55 to 3.93
  • Abemaciclib + Nonsteroidal Aromatase Inhibitor (NSAI) vs Placebo + NSAI · Mixed Models Analysis · p = 0.340 · Lsmean difference: 1.67 · 95% CI -1.77 to 5.10
  • Abemaciclib + Nonsteroidal Aromatase Inhibitor (NSAI) vs Placebo + NSAI · Mixed Models Analysis · p = 0.182 · Lsmean difference: -2.17 · 95% CI -5.37 to 1.03
  • Abemaciclib + Nonsteroidal Aromatase Inhibitor (NSAI) vs Placebo + NSAI · Mixed Models Analysis · p = 0.678 · Lsmean difference: -0.88 · 95% CI -5.05 to 3.29
  • Abemaciclib + Nonsteroidal Aromatase Inhibitor (NSAI) vs Placebo + NSAI · Mixed Models Analysis · p = 0.355 · Lsmean difference: 1.57 · 95% CI -1.77 to 4.91
  • Abemaciclib + Nonsteroidal Aromatase Inhibitor (NSAI) vs Placebo + NSAI · Mixed Models Analysis · p = 0.372 · Lsmean difference: 0.95 · 95% CI -1.14 to 3.03
  • Abemaciclib + Nonsteroidal Aromatase Inhibitor (NSAI) vs Placebo + NSAI · Mixed Models Analysis · p = 0.740 · Lsmean difference: 0.740 · 95% CI -3.75 to 2.66
  • Abemaciclib + Nonsteroidal Aromatase Inhibitor (NSAI) vs Placebo + NSAI · Mixed Models Analysis · p = 0.240 · Lsmean difference: 2.16 · 95% CI -1.46 to 5.78
  • Abemaciclib + Nonsteroidal Aromatase Inhibitor (NSAI) vs Placebo + NSAI · Mixed Models Analysis · p = 0.673 · Lsmean difference: -0.81 · 95% CI -4.60 to 2.97
  • Abemaciclib + Nonsteroidal Aromatase Inhibitor (NSAI) vs Placebo + NSAI · Mixed Models Analysis · p = 0.001 · Lsmean difference: 5.65 · 95% CI 2.23 to 9.07
  • Abemaciclib + Nonsteroidal Aromatase Inhibitor (NSAI) vs Placebo + NSAI · Mixed Models Analysis · p = 0.375 · Lsmean difference: -1.57 · 95% CI -5.04 to 1.91
  • Abemaciclib + Nonsteroidal Aromatase Inhibitor (NSAI) vs Placebo + NSAI · Mixed Models Analysis · p = 0.000 · Lsmean difference: 15.82 · 95% CI 12.81 to 18.84
  • Abemaciclib + Nonsteroidal Aromatase Inhibitor (NSAI) vs Placebo + NSAI · Mixed Models Analysis · p = 0.557 · Lsmean difference: -1.75 · 95% CI -7.59 to 4.10
  • Abemaciclib + Fulvestrant vs Placebo + Fulvestrant · Mixed Models Analysis · p = 0.169 · Lsmean difference: -3.47 · 95% CI -8.43 to 1.49
  • Abemaciclib + Fulvestrant vs Placebo + Fulvestrant · Mixed Models Analysis · p = 0.400 · Lsmean difference: 1.58 · 95% CI -2.12 to 5.29
  • Abemaciclib + Fulvestrant vs Placebo + Fulvestrant · Mixed Models Analysis · p = 0.472 · Lsmean difference: -1.72 · 95% CI -6.42 to 2.99
  • Abemaciclib + Fulvestrant vs Placebo + Fulvestrant · Mixed Models Analysis · p = 0.310 · Lsmean difference: -2.42 · 95% CI -7.12 to 2.28
  • Abemaciclib + Fulvestrant vs Placebo + Fulvestrant · Mixed Models Analysis · p = 0.830 · Lsmean difference: 0.64 · 95% CI -5.26 to 6.55
  • Abemaciclib + Fulvestrant vs Placebo + Fulvestrant · Mixed Models Analysis · p = 0.281 · Lsmean difference: 2.73 · 95% CI -2.26 to 7.72
  • Abemaciclib + Fulvestrant vs Placebo + Fulvestrant · Mixed Models Analysis · p = 0.194 · Lsmean difference: 2.59 · 95% CI -1.33 to 6.52
  • Abemaciclib + Fulvestrant vs Placebo + Fulvestrant · Mixed Models Analysis · p = 0.275 · Lsmean difference: -2.66 · 95% CI -7.45 to 2.14
  • Abemaciclib + Fulvestrant vs Placebo + Fulvestrant · Mixed Models Analysis · p = 0.280 · Lsmean difference: -2.49 · 95% CI -7.04 to 2.06
  • Abemaciclib + Fulvestrant vs Placebo + Fulvestrant · Mixed Models Analysis · p = 0.499 · Lsmean difference: 1.97 · 95% CI -3.78 to 7.72
  • Abemaciclib + Fulvestrant vs Placebo + Fulvestrant · Mixed Models Analysis · p = 0.012 · Lsmean difference: 7.46 · 95% CI 1.68 to 13.23
  • Abemaciclib + Fulvestrant vs Placebo + Fulvestrant · Mixed Models Analysis · p = 0.321 · Lsmean difference: -2.28 · 95% CI -6.83 to 2.27
  • Abemaciclib + Fulvestrant vs Placebo + Fulvestrant · Mixed Models Analysis · p = 0.000 · Lsmean difference: 17.83 · 95% CI 13.25 to 22.41
  • Abemaciclib + Fulvestrant vs Placebo + Fulvestrant · Mixed Models Analysis · p = 0.342 · Lsmean difference: 2.99 · 95% CI -3.21 to 9.19
  • Abemaciclib + Fulvestrant vs Placebo + Fulvestrant · Mixed Models Analysis · p = 0.310 · Lsmean difference: -2.42 · 95% CI -7.12 to 2.28
SecondaryPharmacokinetics (PK): Area Under the Concentration Curve of Abemaciclib, Its Metabolites (M2 & M20)

Pharmacokinetics (PK): Area Under the Concentration Curve of Abemaciclib and its Metabolites LSN2839567 (M2) \& LSN3106726 (M20) was reported. C=Cycle, D=day;

Time frame:
C1D1 post dose, C2D1 post dose, C3D1 predose, C4D1 predose
Reported as:
Geometric mean · Nanogram*hour per Millilitre (ng*h/mL)
Pharmacokinetics (PK): Area Under the Concentration Curve of Abemaciclib, Its Metabolites (M2 & M20)
Nanogram*hour per Millilitre (ng*h/mL)Abemaciclib + Nonsteroidal Aromatase Inhibitor (NSAI)Abemaciclib + Fulvestrant
Abemaciclib2720 ± 402740 ± 57
LSN2839567 (M2)1080 ± 84861 ± 120
LSN3106726 (M20)1970 ± 811570 ± 110

Adverse events

Collected over Up to 28 Months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Abemaciclib + Nonsteroidal Aromatase Inhibitor (NSAI)20/205 (9.8%)40/205 (19.5%)204/205 (99.5%)
Placebo + NSAI10/99 (10.1%)9/99 (9.1%)85/99 (85.9%)
Abemaciclib + Fulvestrant8/104 (7.7%)16/104 (15.4%)103/104 (99%)
Placebo + Fulvestrant9/53 (17%)4/53 (7.5%)39/53 (73.6%)
Most frequent serious events
Showing 10 of 58
Most frequent serious events
EventAbemaciclib + Nonsteroidal Aromatase Inhibitor (NSAI)Placebo + NSAIAbemaciclib + FulvestrantPlacebo + Fulvestrant
Lung infectionInfections and infestations6/2051/992/1041/53
VomitingGastrointestinal disorders4/2050/990/1040/53
PneumonitisRespiratory, thoracic and mediastinal disorders4/2051/990/1040/53
EmbolismVascular disorders2/2050/992/1040/53
PyrexiaGeneral disorders0/2050/990/1041/53
Bile duct obstructionHepatobiliary disorders0/2050/990/1041/53
HypokalaemiaMetabolism and nutrition disorders2/2050/991/1041/53
Facial nerve disorderNervous system disorders0/2050/990/1041/53
Transient ischaemic attackNervous system disorders0/2050/990/1041/53
CholecystitisHepatobiliary disorders3/2050/991/1040/53
Most frequent other events
Showing 10 of 56
Most frequent other events
EventAbemaciclib + Nonsteroidal Aromatase Inhibitor (NSAI)Placebo + NSAIAbemaciclib + FulvestrantPlacebo + Fulvestrant
White blood cell count decreasedInvestigations156/20527/9986/10412/53
Neutrophil count decreasedInvestigations164/20520/9984/10410/53
DiarrhoeaGastrointestinal disorders164/20515/9982/1045/53
AnaemiaBlood and lymphatic system disorders127/20520/9973/1048/53
Platelet count decreasedInvestigations90/2057/9943/1045/53
Alanine aminotransferase increasedInvestigations71/20523/9936/10412/53
Aspartate aminotransferase increasedInvestigations71/20521/9932/10414/53
FatigueGeneral disorders60/20525/9924/1048/53
NauseaGastrointestinal disorders54/20519/9919/1049/53
Decreased appetiteMetabolism and nutrition disorders48/20511/9923/1046/53

Baseline characteristics

All randomized participants.

Age, Continuous
Age, Continuous(years)Abemaciclib + Nonsteroidal Aromatase Inhibitor (NSAI)Placebo + NSAIAbemaciclib + FulvestrantPlacebo + FulvestrantTotal
Mean56.4 ± 10.855.5 ± 9.859.7 ± 8.558.2 ± 10.357.1 ± 10.1
Sex: Female, Male
Sex: Female, Male(Participants)Abemaciclib + Nonsteroidal Aromatase Inhibitor (NSAI)Placebo + NSAIAbemaciclib + FulvestrantPlacebo + FulvestrantTotal
Female2079910453463
Male00000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Abemaciclib + Nonsteroidal Aromatase Inhibitor (NSAI)Placebo + NSAIAbemaciclib + FulvestrantPlacebo + FulvestrantTotal
Hispanic or Latino00000
Not Hispanic or Latino00000
Unknown or Not Reported2079910453463
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Abemaciclib + Nonsteroidal Aromatase Inhibitor (NSAI)Placebo + NSAIAbemaciclib + FulvestrantPlacebo + FulvestrantTotal
American Indian or Alaska Native00000
Asian182899448413
Native Hawaiian or Other Pacific Islander00000
Black or African American12115
White2488444
More than one race00101
Unknown or Not Reported00000
Region of Enrollment
Region of Enrollment(Participants)Abemaciclib + Nonsteroidal Aromatase Inhibitor (NSAI)Placebo + NSAIAbemaciclib + FulvestrantPlacebo + FulvestrantTotal
China164828945380
Brazil21810544
South Africa42017
India1875232
08

Study locations

45 sites
09

References and documents

Publications

  • Hu X, Zhang Q, Sun T, Yin Y, Li H, Yan M, Tong Z, Li M, Teng Y, Oppermann CP, Kanakasetty GB, Portugal MC, Yang L, Zhang W, Jiang Z. Abemaciclib plus non-steroidal aromatase inhibitor or fulvestrant in women with HR+/HER2- advanced breast cancer: Final results of the randomized phase III MONARCH plus trial. Chin Med J (Engl). 2025 Jun 20;138(12):1477-1486. doi: 10.1097/CM9.0000000000003151. Epub 2024 Oct 10. PubMed 39385327 ↗
  • Zhang QY, Sun T, Yin YM, Li HP, Yan M, Tong ZS, Oppermann CP, Liu YP, Costa R, Li M, Cheng Y, Ouyang QC, Chen X, Liao N, Wu XH, Wang XJ, Feng JF, Hegg R, Kanakasetty GB, Coccia-Portugal MA, Han RB, Lu Y, Chi HD, Jiang ZF, Hu XC. MONARCH plus: abemaciclib plus endocrine therapy in women with HR+/HER2- advanced breast cancer: the multinational randomized phase III study. Ther Adv Med Oncol. 2020 Oct 22;12:1758835920963925. doi: 10.1177/1758835920963925. eCollection 2020. PubMed 33149768 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2016 to primary completion in Mar 2019, 27 months.

Results were first posted in Mar 2020, 1 year after primary completion.

Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's 27 months is below that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
May 4, 2016
First posted
May 5, 2016
StartActual
Dec 5, 2016
Primary completionActual
Mar 29, 2019
CompletionEst.
Mar 2028
Results first posted
Mar 30, 2020
Last update
Feb 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02763566
Responsible party
Sponsor
First posted
May 5, 2016
Start date
Dec 5, 2016
Primary completion
Mar 29, 2019
Completion
Mar 2028 (estimated)
Results posted
Mar 30, 2020
Last update
Feb 5, 2026

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Abemaciclib · Letrozole

Start the discussion